Recommended primary outcomes for clinical trials evaluating hemostatic blood products and agents in patients with bleeding: Proceedings of a National Heart Lung and Blood Institute and US Department of Defense Consensus Conference.

MLA

Spinella, Philip C., et al. “Recommended Primary Outcomes for Clinical Trials Evaluating Hemostatic Blood Products and Agents in Patients with Bleeding: Proceedings of a National Heart Lung and Blood Institute and US Department of Defense Consensus Conference.” The Journal of Trauma and Acute Care Surgery, vol. 91, no. 2S Suppl 2, Aug. 2021, pp. S19–25. EBSCOhost, https://doi.org/10.1097/TA.0000000000003300.

APA

Spinella, P. C., El Kassar, N., Cap, A. P., Kindzelski, A. L., Almond, C. S., Barkun, A., Gernsheimer, T. B., Goldstein, J. N., Holcomb, J. B., Iorio, A., Jensen, D. M., Key, N. S., Levy, J. H., Mayer, S. A., Moore, E. E., Stanworth, S. J., Lewis, R. J., & Steiner, M. E. (2021). Recommended primary outcomes for clinical trials evaluating hemostatic blood products and agents in patients with bleeding: Proceedings of a National Heart Lung and Blood Institute and US Department of Defense Consensus Conference. The Journal of Trauma and Acute Care Surgery, 91(2S Suppl 2), S19–S25. https://doi.org/10.1097/TA.0000000000003300

Chicago

Spinella, Philip C, Nahed El Kassar, Andrew P Cap, Andrei L Kindzelski, Christopher S Almond, Alan Barkun, Terry B Gernsheimer, et al. 2021. “Recommended Primary Outcomes for Clinical Trials Evaluating Hemostatic Blood Products and Agents in Patients with Bleeding: Proceedings of a National Heart Lung and Blood Institute and US Department of Defense Consensus Conference.” The Journal of Trauma and Acute Care Surgery 91 (2S Suppl 2): S19–25. doi:10.1097/TA.0000000000003300.